Casa
mm2 para m2

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Por um escritor misterioso

Descrição
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets, Journal of Hematology & Oncology
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Frontiers The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Frontiers Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Biomedicines, Free Full-Text
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Vaccines, Free Full-Text
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. - Abstract - Europe PMC
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
IJMS, Free Full-Text
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Li Zhang, PhD UCSF Global Cancer Program
de por adulto (o preço varia de acordo com o tamanho do grupo)